JPWO2020140084A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020140084A5 JPWO2020140084A5 JP2021537082A JP2021537082A JPWO2020140084A5 JP WO2020140084 A5 JPWO2020140084 A5 JP WO2020140084A5 JP 2021537082 A JP2021537082 A JP 2021537082A JP 2021537082 A JP2021537082 A JP 2021537082A JP WO2020140084 A5 JPWO2020140084 A5 JP WO2020140084A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cdr3
- cdr2
- cdr1
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 44
- 108091000831 antigen binding proteins Proteins 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 13
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 11
- 102000043321 human CTLA4 Human genes 0.000 claims description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 9
- 108091033319 polynucleotide Proteins 0.000 claims description 9
- 239000002157 polynucleotide Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024014900A JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2025100129A JP7854093B2 (ja) | 2018-12-27 | 2025-06-16 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785659P | 2018-12-27 | 2018-12-27 | |
| US62/785,659 | 2018-12-27 | ||
| PCT/US2019/068820 WO2020140084A1 (en) | 2018-12-27 | 2019-12-27 | Anti-ctla-4 binding proteins and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014900A Division JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022516071A JP2022516071A (ja) | 2022-02-24 |
| JPWO2020140084A5 true JPWO2020140084A5 (https=) | 2023-01-10 |
| JP2022516071A5 JP2022516071A5 (https=) | 2023-01-10 |
| JP7558949B2 JP7558949B2 (ja) | 2024-10-01 |
Family
ID=71126610
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537082A Active JP7558949B2 (ja) | 2018-12-27 | 2019-12-27 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024014900A Active JP7745669B2 (ja) | 2018-12-27 | 2024-02-02 | 抗ｃｔｌａ－４結合タンパク質およびその使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12421311B2 (https=) |
| EP (1) | EP3902821A4 (https=) |
| JP (2) | JP7558949B2 (https=) |
| KR (1) | KR20210121045A (https=) |
| CN (2) | CN119930820A (https=) |
| AU (2) | AU2019413366B2 (https=) |
| BR (1) | BR112021012588A2 (https=) |
| CA (2) | CA3124961C (https=) |
| IL (2) | IL284156B2 (https=) |
| MX (1) | MX2021007848A (https=) |
| SG (1) | SG11202106764YA (https=) |
| WO (1) | WO2020140084A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3002957A1 (en) * | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| AU2019413366B2 (en) | 2018-12-27 | 2025-06-05 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| CA3184082A1 (en) * | 2020-07-02 | 2022-01-06 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
| JP2024502035A (ja) * | 2020-12-31 | 2024-01-17 | ノヴァロック バイオセラピューティクス， リミテッド | Ｔｎｆｒ２に対する抗体およびそれの使用 |
| WO2023279068A1 (en) * | 2021-07-02 | 2023-01-05 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| AU2022407541A1 (en) * | 2021-12-10 | 2024-06-13 | Merck Sharp & Dohme Llc | Human mesothelin binders |
| WO2023215560A1 (en) | 2022-05-05 | 2023-11-09 | Atoosa Corporation | Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148079A0 (en) * | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US20110166335A1 (en) | 2000-06-30 | 2011-07-07 | Corbin David R | Xenorhabdus sp. genome sequences and uses thereof |
| TWI320716B (en) * | 2002-10-14 | 2010-02-21 | Abbott Lab | Erythropoietin receptor binding antibodies |
| US20090252741A1 (en) | 2004-09-08 | 2009-10-08 | Ohio State University Research Foundation | Human monoclonal anti-ctla4 antibodies in cancer treatment |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| WO2015092394A1 (en) | 2013-12-17 | 2015-06-25 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
| PT3151921T (pt) * | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| CN108271359B (zh) * | 2015-02-13 | 2021-11-09 | 索伦托药业有限公司 | 结合ctla4的抗体治疗剂 |
| TN2017000440A1 (en) | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| MA44594B1 (fr) * | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| FI3389699T3 (fi) | 2015-12-15 | 2024-05-28 | Oncoc4 Inc | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
| CN120173123A (zh) | 2017-02-27 | 2025-06-20 | 蜻蜓疗法股份有限公司 | 靶向caix、ano1、间皮素、trop2、cea或紧密连接蛋白-18.2的多特异性结合蛋白 |
| US11643463B2 (en) * | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| AU2019413366B2 (en) | 2018-12-27 | 2025-06-05 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| EP3914355A1 (en) | 2019-01-21 | 2021-12-01 | Sanofi | Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers |
| CA3184082A1 (en) | 2020-07-02 | 2022-01-06 | David Scott Johnson | Anti-ctla-4 binding proteins and methods of use thereof |
-
2019
- 2019-12-27 AU AU2019413366A patent/AU2019413366B2/en active Active
- 2019-12-27 IL IL284156A patent/IL284156B2/en unknown
- 2019-12-27 CA CA3124961A patent/CA3124961C/en active Active
- 2019-12-27 US US17/418,776 patent/US12421311B2/en active Active
- 2019-12-27 IL IL316757A patent/IL316757A/en unknown
- 2019-12-27 SG SG11202106764YA patent/SG11202106764YA/en unknown
- 2019-12-27 KR KR1020217023740A patent/KR20210121045A/ko active Pending
- 2019-12-27 BR BR112021012588-4A patent/BR112021012588A2/pt unknown
- 2019-12-27 WO PCT/US2019/068820 patent/WO2020140084A1/en not_active Ceased
- 2019-12-27 EP EP19902920.8A patent/EP3902821A4/en active Pending
- 2019-12-27 CN CN202510014877.4A patent/CN119930820A/zh active Pending
- 2019-12-27 JP JP2021537082A patent/JP7558949B2/ja active Active
- 2019-12-27 MX MX2021007848A patent/MX2021007848A/es unknown
- 2019-12-27 CA CA3249127A patent/CA3249127A1/en active Pending
- 2019-12-27 CN CN201980092796.9A patent/CN114008071B/zh active Active
-
2024
- 2024-02-02 JP JP2024014900A patent/JP7745669B2/ja active Active
-
2025
- 2025-08-27 AU AU2025223772A patent/AU2025223772A1/en active Pending